Chemi S.p.a.

Biovail Laboratories International S.r.l.

Italfarmaco Sud S.p.a.

Biovail Laboratories, Inc.

Valeant Pharmaceuticals Luxembourg S.à.r.l.

Valeant International Srl

Pietro Massardo

Stefano Turchetta

Lorenzo De Ferra

Paul Maes

Werner Oberegger

Mohammad Ashty Saleh

Oreste Piccolo

Graham Jackson

Fang Zhou

Umberto Ciambecchini

Fausto Bonifacio

Valentina Aromatario

Giorgio Cignarella

Stefano Servi

Angela Tuozzi

Paolo Casellato

Guido Cifarelli

Sandra Rondinini

Patrizia R Mussini

Stefano Tur{overscore (c)}hetta

The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

Modified release formulations of a bupropion salt

The present invention relates to a purifying process for phosphatidylserine, the latter being prepared by trans-phosphatidylation of phosphatidylcholine with serine in presence of the enzyme D-phospholipase and containing as impurities hydrophilic compounds, proteins and inorganic salts.

Purifying process for phosphatidylserine

Two novel crystalline forms, designated form A and form B of the antibacterial agent 1-cyclopropyl-7-(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy -4-oxo-3-quinoline carboxylic acid hydrochloride of formula, the preparation thereof, and their pharmaceutical compositions are described. These crystalline forms, which are characterized by greater ability and ease of preparation and of formulation, can be produced by industrially applicable methods which comprises the steps of: a) suspending 1-cyclopropyl-7-(S,S)-2,8-diazabicyclo-[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro -8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride in a solvent selected from an alcohol and a polyalcohol, b) heating the mixture under reflux, c) cooling, d) isolating the product which is separated, (form A) and, additionally, e), reslurrying the solid at reflux in a solvent selected from alcohols and polyols or mixtures thereof, in which the resulting mixture has an overall water content of between 2.5% and 0.01% by weight, f) isolating the product (form B).

Polymorphs of 1-cyclopropy1-7-([s,s])-2,8-diazadicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof

Modified-release formulations of a bupropion salt

A process for the preparation of 3-pyridil-1-hydroxyethyliden-1,1-biphosphonic acid monosodium salt of formula in an amorphous form, preferably lyophilized, and its pharmaceutical compositions are described. Said amorphous form, characterized by stability and simplicity of preparation and formulation, can be obtained by an industrially applicable lyophilization process, which comprises the steps of:

Amorphous 3-pyridil-1-hydroxyethyliden-1,1-biphosphonic acid monosodium salt and process for the preparation thereof

A process is described for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propaneamine comprising substitution of the sulfonyloxy group of the compound of the formula in which the substituents R and R&#x2033; have the meanings stated in the description,in a solvent comprising an ionic liquid,to yield the tertiary amine of the formula and the subsequent deprotection thereof.

Process for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propaneamine

A process for preparing alendronate sodium includes the reaction of gammabutyric acid with phosphorous acid and phosphorus trichioride and subsequent treatment with an aqueous solution of an alkali metal hydroxide, in which the reaction is conducted in liquid ionic solvents.

Preparation of biphosphonic acids and salts thereof

Process for preparing sulfinyl derivatives of Formula 2, useful as inhibitors of gastric acid secretion, comprising the selective oxidation of the corresponding sulfides of formula 1, as represented in the following scheme  The oxidation is performed with hydrogen peroxide in the presence of low amounts of a rhenium compound as catalyst, at a temperature from 0&#xb0; C. to room temperature.

Process for the preparation of sulphinyl derivatives by oxidation of the corresponding sulfides

Purification process of iohexol comprising the treatment of said product with 1-methoxy-2-propanol either alone or mixed with other solvents.

Process for the production of high purity iohexol

Growing community of inventors

Rome, Italy

Pietro Massardo